Notizie dei mercati

Halozyme Therapeutics, Inc.: Goldman Sachs conferma il rating Buy

This content has been archived. It may no longer be relevant

Halozyme Therapeutics, Inc.: Goldman Sachs conferma il rating Buy

Halozyme Therapeutics Goldman


FIMA2681# 2022-08-10T17:01:20+02:00

Show More